medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2018; 70 (2)


Correlation between Lung and Joint Involvement in Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Cross-Sectional Study

Paulin F, Mercado JF, Fernández ME, Caro FM, Alberti ML, Fassola LA

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 76-81
Archivo PDF: 76.32 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269-81.

  2. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med. 1998;19:667-85, viii.

  3. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372-8.

  4. Restrepo JF, del Rincón I, Battafarano DF, et al. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol. 2015;34:1529-36.

  5. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81-91.

  6. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritisassociated interstitial lung disease: Radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583-8.

  7. Assayag D, Lee JS, King TE Jr. Rheumatoid arthritis associated interstitial lung disease: A review. Medicina (B Aires). 2014; 74:158-65.

  8. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322-8.

  9. Pérez-Dórame R, Mejía M, Mateos-Toledo H, Rojas-Serrano J. Rheumatoid arthritis-associated interstitial lung disease: Lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatol Clin. 2015;11:12-6.

  10. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases. Semin Arthritis Rheum. 2011; 41:256-64.

  11. Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B, et al. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med. 2015;30:104-9.

  12. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36:172-8.

  13. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British society for rheumatology biologics register. Ann Rheum Dis. 2010; 69:1086-91.

  14. Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: Shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Invest Clin. 2015;67:280-6.

  15. Aletaha D, Neogi T, Silman AJ, et al 2010 rheumatoid arthritis classification criteria: An American college of rheumatology/ European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

  16. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954-60.

  17. Singh JA, Furst DE, Bharat A, et al 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying Antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-39.

  18. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005;26:153-61.

  19. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

  20. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system Am J Respir Crit Care Med. 2008;177:1248-54.

  21. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology [STROBE] statement: Guidelines for reporting observational studies. Gac Sanit. 2008;22:144-50.

  22. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: A report from China. Rheumatol Int. 2012;32:669-73.

  23. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159-66.

  24. Fischer A, Solomon JJ, du Bois RM, Deane KD, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective Tissue disease. Respir Med. 2012;106:1040-7.

  25. Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28:611-3.

  26. Ye W, Fifield MC, Östör AJ. Refractory rheumatoid arthritis and associated interstitial lung disease: Could abatacept be the answer? J Clin Rheumatol. 2017;23:125-6.

  27. Wuyts WA, Cavazza A, Rossi G, et al. Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? Eur Respir Rev. 2014;23:308-19.

  28. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus- associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006; 116:3183-94.

  29. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000;43:2619-33.

  30. Chatzidionisyou A, Catrina AI. The lung in rheumatoid arthritis, cause or consequence? Curr Opin Rheumatol. 2016;28:76-82.

  31. Paulin F, Babini A, Mamani M, Mercado J, Caro F. Practical approach to the evaluation and management of rheumatoid arthritis- interstitial lung disease based on its proven and hypothetical mechanisms. Rev Invest Clin. 2017;69:235-42.

  32. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: Evolution after treatment. Reumatol Clin. 2012;8:68-71.

  33. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thinsection CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977-83.




2020     |     www.medigraphic.com